The skeleton is the preferred site for prostate cancer (PC) metastasis leading to incurable castrationresistant disease. The increased expression of genes encoding steroidogenic enzymes found in bone metastatic tissue from patients suggests that up-regulated steroidogenesis might contribute to tumor growth at the metastatic site. Because of the overall sclerotic phenotype, we hypothesize that osteoblasts regulate the intratumoral steroidogenesis of castration resistant prostate cancer (CRPC) in bone. We here show that osteoblasts alter the steroidogenic transcription program in CRPC cells, closely mimicking the gene expression pattern described in CRPC. Osteoblast-stimulated LNCaP-19 cells displayed an increased expression of genes encoding for steroidogenic enzymes (CYP11A1, HSD3B1, and AKR1C3), estrogen signaling-related genes (CYP19A1, and ESR2), and genes for DHT-inactivating enzymes (UGT2B7, UGT2B15, and UGT2B17). The observed osteoblast-induced effect was exclusive to osteogenic CRPC cells in contrast to osteolytic PC-3 and androgen-dependent LNCaP cells. The altered steroid enzymatic pattern was specific for the intratibial tumors and verified by immunohistochemistry in tissue specimens from LNCaP-19 xenograft tumors. Additionally, the overall steroidogenic effect was reflected by corresponding levels of progesterone and testosterone in serum from castrated mice with intratibial xenografts. A bi-directional interplay was demonstrated since both proliferation and Esr2 expression of osteoblasts were induced by CRPC cells in steroid-depleted conditions. Together, our results demonstrate that osteoblasts are important mediators of the intratumoral steroidogenesis of CRPC and for castrationresistant growth in bone. Targeting osteoblasts may therefore be important in the development of new therapeutic approaches.
Introduction
Androgen-deprivation therapy (ADT) is first-line therapy for advanced prostate cancer (PC) and is initially effective in the majority of patients. However, castration-resistant prostate cancer (CRPC) inevitably develops within a few years (Mohler et al., 2004; Nishiyama et al., 2004) . Bone metastasis is the most frequent outcome for patients with advanced stage disease, even if the frequency of other metastatic sites, including soft tissue, is increasing in CRPC. The sclerotic response of CRPC suggests that osteoblasts, the cells responsible for bone formation, play a central role in disease progression.
It has become evident that CRPC tumors are not androgenindependent since reactivation of the androgen receptor (AR) is frequently found in CRPC. It is believed that AR is important for the progression of castration resistance and essential for tumor growth (Feldman and Feldman, 2001; Holzbeierlein et al., 2004) . Numerous mechanisms for escaping ADT and restoring AR activity have been described (Culig et al., 2002; Scher et al., 2004) . Mechanisms for sustained AR function are mutations that are rarely found in primary tissue but are more common in CRPC (Barrack, 1996; Marcelli et al., 2000; Taplin et al., 1999; Taplin et al., 1995) . Point mutations in the AR gene have been shown to generate so-called promiscuous receptors which can be stimulated by several different endogenous hormones (Bergerat and Ceraline, 2009; Tan et al., 1997) . Moreover, mutated AR can be activated in a ligand-independent manner by a number of factors, including those derived from osteoblasts (Blaszczyk et al., 2004) .
In addition to altered AR activation, sustained androgen signaling might be due to the maintained intratumoral testosterone levels found in CRPC despite castrate levels in the circulation (Mohler et al., 2004; Montgomery et al., 2008) . This can be explained by the pattern of up-regulated steroidogenic enzymes demonstrated in metastatic CRPC (Hofland et al., 2010; Jernberg et al., 2013; Montgomery et al., 2008; Pfeiffer et al., 2011; Stanbrough et al., 2006) . How this process is regulated is still unclear, but its importance is demonstrated by the response to abiraterone (Zytiga), a CYP17A1 inhibitor, in many CRPC patients. However, despite improvements targeting the AR-axis and enzymatic steps in steroidogenesis, resistance inevitably develops and remains the major obstacle for long-term survival.
Although it is well established that steroids are of utmost importance for both PC and bone, the effect of castration on metastatic growth in bone is poorly investigated. Steroid hormones are the key regulators of bone growth and homeostasis (Vanderschueren et al., 2004) . The direct role of estrogen is to inhibit bone resorption by affecting osteoblast secretion, including increased osteoprotegerin (OPG) and decreased receptor activator of NF kappa В ligand (RANKL) and tumor necrosis factor alpha (TNF) (Eghbali-Fatourechi et al., 2003; Hofbauer et al., 1999; Hofbauer and Schoppet, 2004; Modder et al., 2011; Roggia et al., 2001) . The main role of testosterone in bone is to serve as a substrate for aromatization into estrogen by CYP19A1. Moreover, osteoblast AR signaling has been reported to be important to maintain the trabecular bone mass (Chiang et al., 2009; Notini et al., 2007) .
Recently, we presented a sclerotic CRPC model based on LNCaP-19 cells, and demonstrated that castration resistance promotes the osteogenic phenotype of PC and that osteoblasts further potentiate osteomimicry of tumor cells (Hagberg Thulin et al., 2014) . Furthermore, we and others have shown that soluble factors derived from osteoblasts stimulate the progression of an aggressive phenotype and stimulate the androgen-signaling axis of PC cells (Wang et al., 2009 ).
The current study shows that osteoblasts contribute to castration-resistant growth of PC in bone by inducing steroidogenesis. Our results emphasize the interaction between osteoblasts and CRPC as a possible therapeutic target to inhibit the development of castration-resistance.
Material and methods

Cell culture and conditioned medium
The in vitro developed osteogenic CRPC cell line LNCaP-19 has been characterized previously (Gustavsson et al., 2005; Hagberg Thulin et al., 2014) . The androgen-dependent LNCaP cell line was obtained from the American Type Culture Collection (ATCC, Rockville, MD) and osteolytic PC-3 cells from the European Collection of Cell Cultures (ECCC, Wiltshire, UK). MC3T3-E1 clone 4 and NIH3T3 cells were obtained from ATCC. Cells were cultured as previously described (Hagberg Thulin et al., 2014) . Cells were used in passages below 20, and confirmed mycoplasma free.
Cell-conditioned medium (CM) was obtained as previously described. The following media were collected: osteoblast conditioned medium (OCM), fibroblast conditioned medium (FCM), LNCaP-19 conditioned medium (L19CM), LNCaP conditioned medium (LNCaPCM) and PC-3 conditioned medium (PC-3CM).
RNA isolation and reverse transcription
Total RNA was extracted using the RNeasy Mini Plus kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. A total of 1 mg RNA per reaction was reverse transcribed into cDNA using the VILO Superscript cDNA synthesis kit (Invitrogen) according to the manufacturer's instructions.
QPCR
Gene expression analysis was performed on an ABI Prism 7500 Fast Sequence Detector (Applied Biosystems, Foster City, CA). The specific TaqMan gene expression assays (Applied Biosystems) used are specified in Supplementary Table 1 (S1). The expression levels of each sample were normalized against 18S and GAPDH. PCR parameters were according to the manufacturer's protocol, and the DDCt method was used for relative mRNA quantification. PCR reactions were performed in independent triplicates for all samples.
Androgen gene signature analysis
Comparative analysis of androgen-related genes between LNCaP-19, LNCaP and PC-3 cells upon OCM stimulation was assessed using a human androgen gene signature array (Applied Biosystems; TaqMan ® Array Gene Signature plate # 4418728). The array included 96 androgen-related genes and endogenous control genes (for a complete list of genes included, see www. appliedbiosystems.com). Briefly, cells were serum-starved for 24 h before the addition of control medium or OCM supplemented with 1.5% CSS. FCM was used as control. Cultures were maintained for 48 h before RNA extraction. Five ng cDNA was used for the PCR reactions. Parameters were set according to the manufacturer's protocol and the DDCt method was used for relative mRNA quantification. The expression levels were normalized against 18S and GUSB. Genes with more than a 2-fold change in transcription compared to controls are shown. Calculations are based on the mean 2 ÀDDCt values from three independent experiments. Genes were considered to be non-detected in cases where Ct values were above 36.
Protein isolation and Western blot
Proteins were isolated from whole cells in cellytic M lysis buffer (Sigma Aldrich) containing phosphatase inhibitor and protease inhibitor cocktail (Roche Diagnosis, Mannheim, DE) for 15 min on ice followed by centrifugation (16.000Â g) and supernatant collection. Protein concentrations were determined using the BSA protein assay kit (Pierce Biotechnology, Rockford, IL, US), this according to the manufacturer's protocol. For western blot analysis, cell lysates of 15 mg protein were resuspended in NuPage LDS sample buffer/NuPage reducing agent, separated on a 4e12% BiseTris gradient gel with MOPS-running buffer and transferred onto polyvinyldifluoride (PVDF) membranes using the i-Blot gel transfer system (all above products were purchased from Invitrogen, Carlsbad, CA, US). The membranes were blocked in 2% blocking solution (RPN2135, Amersham™, GE Healthcare, Buckinghamshire, UK) in PBST for 1 h in RT and incubated with primary antibodies over night at 4 C. Membranes were washed and incubated with a hourseradish-peroxidase (HRP)-labeled secondary antibody for 1 h at RT. The immunoreactions were detected using the ECL advanced western blotting detection system (RPN2135, Amersham™, GE Healthcare). The following anti-human primary antibodies were used: anti-AR (Santa Cruz: sc7305), anti-AKR1C3 (Abcam: ab84327), anti-CYP11A1 (Abcam: ab75497), anti-CYP19A1 (Abcam: ab69653), anti-ERb (Thermo Scientific: PA1-311), anti-HSD3B1 (Abcam: ab55268). As loading control, anti-b-actin (Abcam: ab8227) was used. Detailed information regarding host species and dilutions are specified in Supplementary Table 2 (S2).
Cell proliferation
Osteoblasts were seeded in 96-well plates at a density of 3.5 Â 10 3 cells per well in alpha-MEM with 10% CSS. On day two, the medium was changed to CM from LNCaP, LNCaP-19, PC-3 or control medium (alpha-MEM). Proliferation was monitored after 48 and 120 h by the BrdU ELISA colorimetric assay (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions.
Animals and implantations of cells
The protocol was approved by the local Committee on the Ethics of Animal Experiments of Gothenburg (Permit Number: 316-2011 , 317-2011 and 281-2011 .
Intratibial injections were performed as previously described (Hagberg Thulin et al., 2014; Jennbacken et al., 2012) . Briefly, eightweek-old Balb/c nude mice (Charles River Laboratories International, Inc., Wilmington, MA) were anesthetized with isoflurane. The left leg was flexed to a 90 angle and a 29-gauge needle was inserted via the knee joint, into the proximal end of the tibia. 400,000 LNCaP-19 cells in 7 mL Matrigel (BD Bioscience, Bedford, MA) were injected into the bone marrow cavity. The mice were castrated directly after cell implantation. The experiment was ended after 10 weeks. Blood was collected and stored as serum at À80 C until analysis. For histological evaluation, the tibiae were dissected and fixed in formalin, decalcified in modified formic acid or EDTA and embedded in paraffin. Tumor establishment was assessed in sections of the central part of the bone marrow.
Subcutaneous injections were performed as previously described (Gustavsson et al., 2005) . Briefly, two million LNCaP-19 cells in 100 mL culture medium and 100 mL Matrigel were implanted subcutaneously in the flank of castrated mice. Tumors were measured with a caliper and the experiment was ended when tumor size reached about 1.3 cm 3 .
Orthotopic injections were performed as previously described (Jennbacken et al., 2009 ). Briefly, a transversal incision was made in the lower abdomen, and castration was performed prior to cell injection. One million LNCaP-19 cells suspended in 7 mL Matrigel were injected into the dorsolateral lobe of the prostate using a 30-gauge needle. Animals were sacrificed after 9 weeks. Tumors were fixed in formalin for paraffin embedding.
Immunohistochemistry
Immunohistochemistry was performed using the Vectastain Elite ABC kit (Vector Laboratories, Inc., Burlingame, CA) according to the manufacturers instruction. Before staining, tissue sections (4 mm) were pre-heated at 60 C for 10 min, deparaffinized and rehydrated in ethanol. For antigen retrieval and endogenous peroxidase blockage, sections were heated in unmasking solution (Vector Laboratories, Inc.) and incubated in 0.3% hydrogen peroxidase in methanol. The following anti-human primary antibodies were used: anti-AR (Santa Cruz: sc7305), anti-AKR1C3 (Abcam: ab84327), anti-CYP11A1 (Abcam: ab75497), anti-CYP19A1 (Abcam: ab69653), anti-ERa (Cell signaling: C8644), anti-ERb (Thermo Scientific: PA1-311), anti-HSD3B1 (Abcam: ab55268) and anti-PrR (Cell signaling: C89F7). Detailed information regarding host species and dilutions are specified in Supplementary Table 2 (S2). Antihuman AR was used as positive control for all tissues. As negative controls, immunohistochemistry was performed without primary antibodies or with a class-matched isotype control.
Serum steroid measurements
Serum concentration of progesterone, androstenedione, testosterone, estradiol, estrone and dihydrotestosterone (DHT) were measured in serum in a single run by GCeMS/MS. Briefly, after addition of isotope-labeled standards, steroids were extracted to chlorobutane, purified on a silica column and derivatized using pentafluorobenzylhydroxylamine hydrochloride followed by pentafluorobenzoyl chloride. Steroids were analyzed in multiple reaction monitoring mode with ammonia as reagent gas using an Agilent 7000 triple quadrupole mass spectrometer equipped with a chemical ionization source (Nilsson et al., 2015) .
The limits of quantification (LOQ) for estradiol, estrone, testosterone, DHT, progesterone and androstenedione were 0.5, 0.5, 8, 2.5, 74, and 12 pg/ml, respectively. The intra-assay coefficients of variation (CVs) were below 14% and the inter-assay CVs below 11%. Serum from castrated male mice with and without intratibial LNCaP-19 tumors was compared (n ¼ 6 pooled samples, each from 2 to 3 mice, per group).
ELISA
Osteoblastic serum markers (OPG and RANKL) were measured using mouse-specific ELISAs in accordance with the manufacturer's instructions (Abcam, Cambridge, UK). Mouse serum was diluted 1:10 and 1:3 for measurement of OPG and RANKL, respectively. Absorbance was read at 450 nm on a Wallac 1420 Victor3TM multiplate reader (PerkinElmer Inc, Shelton, CT).
Functional assay of the androgen receptor activity in LNCaP-19 cells
AR mutations were screened for in an activity assay in the recombinant EJ250 yeast strain (MATa ade2-101 his3-D200 leu2-D1 lys2-801 trp1-D1 ura3-52 URA3:ARE-ADE2[pRS/AREAde2]) (Ceraline et al., 2003; Lapouge et al., 2007; Marcias et al., 2010) . In EJ250, expression of the ADE2 reporter gene, necessary for adenine biosynthesis, was controlled by an androgen-dependent promoter. RNA was prepared from cell lines (RNeasy Midi Kit, Qiagen), and AR cDNA fragments were amplified with forward (nucleotides 2310e2339) and reverse (nucleotides 4075e4101) primers flanking exons 1e8 (GenBank NM_000044.2, nucleotides 2310e4101). 100 ng of AR cDNA fragments were inserted into a yeast expression gap repair plasmid by homologous recombination. EJ250 were transformed with the AR expression plasmid (Ceraline et al., 2003) , and plated on selective media depleted of adenine containing either DHT, estrogen, or progesterone (Sigma Aldrich, St Quentin Fallavier, France) at the indicated concentrations. A negative control (vehicle) and a positive control (supplemented with adenine) were also included. The AR-dependent yeast growth in response to steroids was evaluated by colony scoring after incubation at 30 C for 72 h (Ceraline et al., 2003) . The wild-type AR was assayed as a control. Histograms correspond to the ratio of the number of yeast colonies scored to the number of colonies obtained in the presence of 10 nM DHT. In this yeast-based system, 10 nM DHT leads to a detectable AR activity (Ceraline et al., 2003) . Saturation was obtained at 100 nM DHT, and data obtained with doses lower that 10 nM remained as background levels.
Statistics
Statistical calculations were performed using the SPSSv20 software package (SPSS, Chicago, IL). Statistical differences between groups were measured with Student's t-test or the ManneWhitney U-test where appropriate. All data are presented as mean ± SEM. A P-value of <0.05 was considered significant.
Results
Gene expression profiles of the androgen synthesis pathway in prostate cancer cell lines
To gain insight in the mechanisms driving steroidogenesis in CRPC, we compared the basal gene transcription of the key steps in steroidogenesis and steroid signaling in three PC cell lines, LNCaP, LNCaP-19 and PC-3. LNCaP is androgen-dependent with poor potential to grow in bone, its castration-resistant derivate LNCaP-19 is castration-resistant and forms sclerotic lesions in bone (Hagberg Thulin et al., 2014) , while PC-3 is castration-resistant and forms lytic lesions in bone (Kaighn et al., 1979) . The differences between the cell lines are presented in Table 1 . LNCaP and LNCaP-19 displayed a similar basal gene transcription pattern of steroidogenic enzymes covering all the steps for de novo steroidogenesis from cholesterol and androgen precursors. The exception was HSD17B3, catalyzing the conversion of androstenedione to testosterone, which was only expressed in LNCaP-19 cells. In contrast to LNCaP-19, PC-3 did not express any of the glucuronide enzymes UGT2B7, UGT2B15, and UGT2B17, which primarily catalyze the glucuronidation of the active DHT into inactive water-soluble derivatives. As expected, both LNCaP and LNCaP-19 cells express high levels of AR mRNA, which was also detected, albeit to a markedly lower extent, in PC-3 cells. Essential genes of the estrogen synthesis pathway, such as CYP19A1 and estrogen receptor alpha (ESR1) were only detected in the castration-resistant cell lines. For the complete gene array list, see Supplementary Table 3 (S3).
Osteoblasts alter the transcription of steroidogenic enzymes in osteogenic CRPC cells
Next, we assessed the effect of osteoblast conditioned medium (OCM) on the expression of steroidogenic enzymes in LNCaP, LNCaP-19 and PC-3. Transcripts encoding the majority of enzymes in the androgen synthesis pathway were influenced by OCM in LNCaP-19 cells in contrast to LNCaP and PC-3, which did not respond to OCM stimulation. OCM induced the expression of 57 of the 92 selected genes involved in the androgen-signaling axis and the steroidogenic pathway in the LNCaP-19 cells (Fig. 1A) (for the complete list, see the Supplementary Table 4 (S4)). In LNCaP-19 cells, the gene expression of AR (P < 0.01), estrogen receptor beta (ESR2) (P < 0.01), CYP11A1 (P < 0.05), HSD3B1 (P < 0.01), and CYP19A1 was significantly upregulated by OCM. Moreover, expression levels of the genes for the glucuronide enzymes e UGT2B7, UGT2B15, and UGT2B17 e were strongly increased by OCM (Fig. 1B) . In addition, gene expression of AKR1C3 was slightly increased by OCM in LNCaP-19. CYP17A1 expression was not affected by osteoblasts in LNCaP-19, and it was not detected in LNCaP (Fig. 1C) . The observed effects were OCM specific since FCM did not induce a similar response (data not shown). The osteoblastinduced changes in gene expression of AR, ESR2, CYP11A1, and CYP19A1 were confirmed on the protein level (Fig. 1D) . In contrast, levels of HSD3B1 protein were not changed by OCM, and AKR1C3 was undetectable (data not shown).
The induced changes in mRNA expression was sustained after 21 days of culture, where AKR1C3, UGT2B17 (P < 0.05), HSD3B1, and CYP19A1 were increased (P < 0.01), while SRD5A1 and SRD5A3 were suppressed (P < 0.05) (Supplementary Fig. S5 ).
These data show that osteoblasts induce the majority of the enzymes previously found to be upregulated in clinical bone metastasis from CRPC patients. Together the altered expression pattern indicates an increased synthesis of mainly progesterone, testosterone and estrogen in parallel with changed DHT metabolism.
Immunohistochemistry of steroidogenic enzymes and steroid receptors in LNCaP-19 xenografts
The osteoblast-induced steroidogenic pattern in LNCaP-19 cells was confirmed with immunohistochemistry on established LNCaP-19 tumors in vivo. Tissue specimens from castrated mice with intratibial tumors demonstrated a marked expression of HSD3B1 and CYP19A1 in the tumor cells compared to weak or absent staining in the subcutaneous and orthotopic LNCaP-19 tumors ( Fig. 2A) . In addition, expression of AKR1C3, the enzyme catalyzing Ct endogenous control ).
****: DCt < 1; ***:DCt < 5; **: DCt < 10; *: DCt < 15. DCt represents the mean value of three biological replicates. ND ¼ not detected.
the conversion of adrenal androgen into testosterone, was confirmed and modestly increased in the intratibial tumor cells compared to in orthotopic and subcutaneous tumors. These results indicate an overall increased steroidogenesis with increased conversion of androstenediol to testosterone and testosterone to estradiol, respectively, in this intratibial model. Consistent with prior reports on skeletal metastasis of CRPC, staining of estrogen receptor beta (ERb) was intense in the nucleus and cytoplasm of LNCaP-19 cells in the intratibial tumors compared to very weak staining in tumor cells in orthotopic and subcutaneous tumors. In contrast to ERb expression, ERa and progesterone receptor (PgR) were solely detected in bone cells. Osteocytes in the newly formed bone, adherent to the interlaced tumor islands, displayed an increase in PgR expression. ERa stained positive in both osteocytes and osteoblasts in conjunction to the tumor areas. AR showed nuclear staining in tumors in all xenograft models (Fig. 2B) . These results indicate bidirectional steroidogenic interplay in response to the sclerotic tumor process of LNCaP-19 with an important role of AR and ERb in tumor cells and in contrast a strong response to estrogen and progesterone in bone.
Intratibial LNCaP-19 tumors secrete steroids detectable in serum from castrated mice
Concentrations of steroids were measured by GCeMS/MS in castrated mice with and without intratibial LNCaP-19 tumors. In accordance with data on steroidogenic enzymes, serum concentrations of progesterone (P < 0.05) and testosterone were increased in mice with intratibial tumors compared to control mice, supporting an overall stimulation of steroidogenesis ( Fig. 3A and C) . Androstenedione levels in serum were not changed in response to intratibial tumor (Fig. 3D) . Supporting our findings of increased expression of DHT-inactivating enzymes, levels of DHT tended to decreased in serum from tumor bearing mice compared to control mice (Fig. 3B) . Levels of estradiol and estrone were below the quantification levels (LOQ 0.5 pg/ml) of the assay. Together, these results demonstrate that the altered expression of steroidogenic enzymes in LNCaP-19 tumors results in steroid production detectable as a systemic effect on steroid levels.
Estrogen-regulated markers are influenced by sclerotic LNCaP-19 xenografts
Since no estradiol or estrone could be detected in serum, we investigated whether effects of local estrogen synthesis within sclerotic intratibial CRPC tumors could be detected systemically. Therefore, we evaluated serum levels of the estrogen-regulated bone turnover markers OPG and RANKL from LNCaP-19 xenografts. These markers are produced by osteoblasts among other cell types, regulating osteoclastogenesis, and well documented to increase and decrease, respectively, in response to estrogen (EghbaliFatourechi et al., 2003; Hofbauer et al., 1999; Lacey et al., 1998) . Serum levels of OPG and RANKL were significantly increased (P ¼ 0.04) and decreased (P ¼ 0.03), respectively, in xenografts with sclerotic LNCaP-19 intratibial tumors ( Fig. 4A and B) . This is in line with in vitro data where mRNA levels of Opg in osteoblasts stimulated with LNCaP-19 CM were increased (P < 0.001) in vitro (Fig. 4C) . Rankl mRNA was below detectable levels in this setting. To summarize, the increased OPG/RANKL ratio indicate a decreased osteoclastogenesis which may be explained by the osteoblast response to an increase of estradiol or testosterone produced locally in sclerotic CRPC tumor in bone.
Androgen receptor mutation and ligand specificity
Since our data supports an altered steroidogenesis in sclerotic CRPC, we further evaluated the responsiveness of AR in LNCaP-19 to ligands other than androgens under castrated condition. LNCaP carries the T877A mutation which renders it responsive to progesterone and estradiol in addition to testosterone and DHT. Since LNCaP-19 is derived from LNCaP, we have sequenced the AR of LNCaP-19 and confirmed the T877A mutation (unpublished data).
Next, the hormone response of LNCaP-19 AR was compared to AR in LNCaP. At low steroid concentrations, corresponding to a castrate condition, AR of LNCaP-19 and LNCaP responded to 10 nM progesterone with more than 10 times higher activity compared to 10 nM DHT (Fig. 5) . These data suggest progesterone might be the main substrate for driving AR activity under a castrated condition in tumors carrying the T877A mutation.
Effect of CRPC stimulation and castrated conditions on osteoblasts
We and others have shown that soluble factors from PC cells stimulate osteoblast growth (Blaszczyk et al., 2004; Lu et al., 2004) . Previous studies were performed in the presence of steroids, therefore we investigated the potential of different PC cell lines to stimulate proliferation of osteoblasts also in a steroid deprived condition (10% CSS). Steroid-deprivation largely inhibited osteoblast growth, but their proliferation was significantly increased by LNCaP-19 CM (P < 0.001), but not by PC-3 CM (P < 0.001) (Fig. 6A) . These data show that the osteoblastic CRPC cells can substitute the growth promoting effect of steroids on osteoblasts.
To further evaluate the impact of castration on the bi-directional interplay interaction between osteoblasts and CRPC cells regarding steroid mediated effects, expression of steroid receptors was ) were implanted in the tibia (n ¼ 8), prostate (n ¼ 5) or subcutaneously (n ¼ 5) in castrated mice, respectively. Panels show representative pictures of A) steroidogenic enzymes, and B) steroid receptors. Arrows show osteocytes and osteoblasts. Original magnification 40Â. Fig. 3 . Serum steroid concentrations in intratibial LNCaP-19 xenografted mice. Serum steroid concentrations measured using GCeMS/MS from castrated control mice and castrated mice with intratibial tumors. A) Progesterone (Limit of quantification (LOQ) 12 pg/ml), B) DHT (LOQ 2.5 pg/ml), C) Testosterone (LOQ 8 pg/ml), D) Androstenedione (LOQ 12 pg/ml). Boxplots indicate the median and the lower and upper quartiles; whiskers indicate maximum and minimum, and data points indicate outliers. n ¼ 6 pooled samples/group, *: P < 0.05. investigated in osteoblasts exposed to CM from LNCaP-19 and PC-3 in both 10% CSS and 10% FBS. Interestingly, Esr2 was significantly upregulated in the steroid depleted condition in all treatments groups. Additionally, LNCaP-19 CM increased Esr2 expression compared to control medium (P < 0.05). While osteoblast expression of Ar and Esr1 were minimally affected by LNCaP-19 CM, Esr1 expression was increased by PC-3 CM in the castrate condition (P < 0.01). In addition, steroid deprivation induced an increase in Ar expression in the control (P < 0.001), an effect that was inhibited by LNCaP-19 CM whereas PC-3 CM had a small stimulatory effect (P < 0.05) (Fig. 6BeD) . These results show that Esr2 is upregulated in osteoblasts in response to castration and by osteoblastic CRPC cells in agreement with ERb in human bone metastatic tissue of CRPC (Fixemer et al., 2003; Lai et al., 2004; Leav et al., 2001 ).
Discussion
There is substantial evidence that PC cells undergo adaptive changes in response to castration that are associated with upregulation of genes encoding steroidogenic enzymes that are involved in the biosynthesis of androgens. This altered mRNA expression pattern has been observed in CRPC bone metastases and is believed to contribute to the castration-resistant tumor growth at the metastatic site. However, the mechanisms driving these molecular alterations are poorly defined. In the current study, we show for the first time that osteoblasts induce and alter the steroidogenic profile in osteogenic CRPC cells.
As summarized in Fig. 7 , the mRNA pattern induced by osteoblasts in LNCaP-19 cells closely mimicking the increased gene expression pattern of steroidogenic enzymes described in human CRPC, including bone metastases (Cai et al., 2011; Holzbeierlein et al., 2004; Montgomery et al., 2008; Pfeiffer et al., 2011; Stanbrough et al., 2006) . The upregulated expression of CYP11A1 in LNCaP-19 cells shows that osteoblasts enable CRPC cells to use cholesterol as the source of their steroidogenesis. CYP11A1 catalyzes the conversion of cholesterol into the androgen precursor pregnenolone in the de novo steroid synthesis pathway. Thus LNCaP-19 is not dependent on adrenal steroids as precursors for testosterone synthesis. One aspect of these findings is the lack of DHEA as a precursor for testosterone synthesis both in vitro and in vivo, since mice lack adrenal CYP17A1 expression, which could suggest that CYP11A1 induction is a response to that specific selection pressure, and may not be representative of the situation in human bone metastases. However, similar to in clinical tumors, the increased in vivo expression of AKR1C3, which mediates the conversion of adrenal androgen into testosterone, shows that the potential to use adrenal precursors was also increased by osteoblasts. In addition, HSD3B1 e which converts androstenediol into testosterone e was increased in vivo. The increased expression of steroidogenic enzymes in the intratibial LNCaP-19 tumors was also reflected by increased levels of progesterone and detectable levels of testosterone in serum from xenografted castrated mice compared to tumor-free mice. Androstenedione levels did not increase in serum, which could reflect an increased metabolism by AKR1C3. Also, osteoblasts in our experiment did not increase the tumor cell expression of CYP17A1, the enzyme catalyzing the conversion of precursors into androstenedione. This is in line with the majority of studies on human CRPC tumors where no increased CYP17A1 expression was detected (Hofland et al., 2010; Holzbeierlein et al., 2004; Jernberg et al., 2013; Pfeiffer et al., 2011; Stanbrough et al., 2006) . However, the blocking of CYP17A1 activity by abiraterone (Zytiga) efficiently inhibits steroidogenesis in CRPC patients, resulting in a prolonged survival. The unchanged levels of CYP17A1 in response to osteoblast-stimulation in this experimental setting may relate to the fact that CRPC cells expressing a T877A mutant AR are not CYP17A1 dependent for their AR activation. Instead, AR activity in these cells may be mediated by intratumoral pregnenolone/progesterone synthesis (Cai et al., 2011) . In line with this, we show that progesterone activates the mtT877A AR to a greater extent than DHT under castrate conditions. These findings suggest that antagonists blocking the binding of progesterone to AR could be a possible therapeutic option for the about 10e40% of PC patients with bone metastases who carry this AR mutation (Taplin et al., 1999 (Taplin et al., , 1995 . Despite the obvious role of AR in sclerotic CRPC cells, as indicated by the induction of many AR-regulated genes in osteoblast-stimulated LNCaP-19 cells, we demonstrate an expression profile of steroidogenic enzymes that supports suppressed DHT activity. Osteoblast-stimulated LNCaP-19 displayed decreased levels of SRD5A1 and SRD5A3, catalyzing the conversion of testosterone to DHT, together with increased levels of UGT2B15 and UGTB217, mediating the irreversible glucuronidation of DHT metabolites. Reflecting this, GCeMS/MS measurements indicated a decrease of DHT in serum from castrated mice with intratibial tumors. These findings might explain part of the decreased intratumoral DHT/testosterone ratio shown in metastatic CRPC tissue compared to primary PC or benign prostate tissue (Mohler et al., 2004; Montgomery et al., 2008; Titus et al., 2005) . Although the main focus on intratumoral steroidogenesis has been on androgens, aromatase (CYP19A1) e the enzyme that catalyze testosterone to estrogen e is altered in CRPC tissue and the expression of CYP19A1 is highly up-regulated in CRPC compared with primary tumors (Ellem et al., 2004; Montgomery et al., 2008) . In the present study, CYP19A1 were exclusively expressed in intratibial LNCaP-19 tumors and in the CRPC cell lines. Together with the prominent expression of ERb in bone metastases (Lai et al., 2004) , this suggest an active estrogen-signaling axis in sclerotic CRPC cells. Furthermore, the staining of ERa in osteoblasts and PgR in both osteoblasts and osteocytes in the newly formed bone of LNCaP-19 tumors, together with the altered serum levels of OPG and RANKL support an increased estrogen response in the sclerotic situation of our model.
The physical role of ERb in human bone biology is not well understood. However, the ratio between ERa and ERb in bone might determine the downstream activities of estrogen. In PC, the ERb expression is dynamic but reemerges as PC metastasizes and is expressed in 100% of bone metastases (Fixemer et al., 2003; Lai et al., 2004) . The strong expression of ERb compared to ERa in LNCaP-19 tumor cells in bone, suggests that ERb might be important for the sclerotic activity of CRPC. In addition to the osteoblastinduced changes in tumor cells, we also demonstrated a reversed stimulatory situation. Osteoblasts, which are normally dependent on steroids for growth in vitro, were stimulated to increased proliferation by LNCaP-19, but not by PC-3, cells under castrate conditions. This indicates that osteogenic CRPC cells substitute steroids, possibly in combination with other factors, which are sufficient to enable osteoblastic growth during ADT.
In conclusion, we show that osteoblasts are important mediators of the intratumoral steroidogenesis of CRPC tumors and for castration-resistant growth in bone. In particular, we emphasize the increased steroidogenesis together with a steroidogenic pattern, indicating a shift from DHT synthesis towards progesterone and estrogen, as a critical part of the vicious cycle of sclerotic CRPC. Importantly, the role of osteoblasts in the progression of CRPC needs to be taken into consideration in the development of new therapeutic approaches.
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